Duloxetine for the treatment of major depressive disorder

Charles Nemeroff, Alan F. Schatzberg, David J. Goldstein, Michael J. Detke, Craig Mallinckrodt, Yili Lu, Pierre V. Tran

Research output: Contribution to journalArticle

184 Scopus citations

Abstract

>55% were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44% versus 16%). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6%) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg QD.

Original languageEnglish (US)
Pages (from-to)106-132
Number of pages27
JournalPsychopharmacology Bulletin
Volume36
Issue number4
StatePublished - Sep 1 2002
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Duloxetine for the treatment of major depressive disorder'. Together they form a unique fingerprint.

  • Cite this

    Nemeroff, C., Schatzberg, A. F., Goldstein, D. J., Detke, M. J., Mallinckrodt, C., Lu, Y., & Tran, P. V. (2002). Duloxetine for the treatment of major depressive disorder. Psychopharmacology Bulletin, 36(4), 106-132.